# A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

> **NCT06091930** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 21 (actual)

## Conditions studied

- Gastrointestinal Cancer
- Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Head and Neck Cancer
- Liver Cancer

## Interventions

- **DRUG:** BI 765049
- **DRUG:** Ezabenlimab

## Key facts

- **NCT ID:** NCT06091930
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-16
- **Primary completion:** 2025-08-15
- **Final completion:** 2025-10-03
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06091930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06091930, "A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT06091930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*